Literature DB >> 6166789

Heterogeneity of beta 2-microglobulin in human breast carcinoma.

M A Weiss, J G Michael, A J Pesce, L DiPersio.   

Abstract

beta 2-microglobulin (beta 2m) content and distribution in human benign and malignant breast tissues have been investigated by immunohistologic means, and wide differences in the expression of this protein have been observed. The distribution of beta 2m as determined by indirect immunofluorescence was uniform throughout normal human and benign breast tumor tissues, as well as in human tumor xenografts grown in athymic mice, but marked difference in beta 2m content was demonstrated between individual tumors. In breast carcinomas, heterogeneity in beta 2m expression was found to exist within individual tumors. This heterogeneity was evident mainly in moderately well-differentiated tumors; the majority of poorly differentiated tumors did not express beta 2m at all. It is suggested that the expression of surface beta 2m is an indicator of tumor cell differentiation or maturation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6166789

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  9 in total

1.  HLA-DR and beta 2 microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entities.

Authors:  M Feinmesser; A Sulkes; S Morgenstern; J Sulkes; S Stern; E Okon
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

2.  Tumor heterogeneity: biological implications and therapeutic consequences.

Authors:  G H Heppner; B E Miller
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

3.  M2PP: a novel computational model for predicting drug-targeted pathogenic proteins.

Authors:  Shiming Wang; Jie Li; Yadong Wang
Journal:  BMC Bioinformatics       Date:  2022-01-04       Impact factor: 3.169

4.  Heterogeneous distribution of actin, myosin, fibronectin and basement membrane antigens in primary and metastatic human breast cancer.

Authors:  P G Natali; P Giacomini; G Bigotti; M R Nicotra; M Bellocci; C De Martino
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

5.  Phenotypic switch from CD45RA+ to CD45RA- by normal blood T cells is associated with increased HLA-ABC expression for CD4+ and CD8+ populations but not for the NK-associated CD4-CD8dim+ or CD4-CD8- fractions.

Authors:  R A Jones; S J Richards; B E Roberts; J A Child; C S Scott
Journal:  Immunology       Date:  1990-05       Impact factor: 7.397

6.  Serum beta 2-microglobulin in chronic diseases of the pancreas.

Authors:  R Pezzilli; P Billi; M Fiocchi; E Beltrandi; O Cappelletti; G Sprovieri; M Miglioli
Journal:  Int J Pancreatol       Date:  1995-04

Review 7.  Heterogeneous expression of cell-surface antigens in normal epithelia and their tumours, revealed by monoclonal antibodies.

Authors:  P A Edwards
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640

8.  Lacking prognostic significance of beta 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas.

Authors:  H O Wintzer; M Benzing; S von Kleist
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640

9.  HLA antigens in colorectal tumours--low expression of HLA class I antigens in mucinous colorectal carcinomas.

Authors:  H F van den Ingh; D J Ruiter; G Griffioen; G N van Muijen; S Ferrone
Journal:  Br J Cancer       Date:  1987-02       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.